Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Medicare Payments for Stelara

Stelara (ustekinumab) is a high-cost prescription biologic approved to treat certain autoimmune diseases. Subcutaneous (under-the-skin) versions of Stelara are typically self-injected and covered under Medicare Part D. Prior to 2023, Medicare Part B also covered subcutaneous versions of Stelara when the injection was administered by a physician; however, Medicare Administrative Contractors now exclude Stelara injections under a policy designed to omit self-administered drugs from Part B coverage. The period during which Stelara was covered under Parts B and D provides a unique opportunity to examine how coverage determinations affect payments made by the Medicare program and costs for its enrollees. OIG will produce two work products related to Medicare payments and utilization trends for the subcutaneous versions of Stelara. The first product will focus on a cost comparison for enrollees with traditional fee-for-service Medicare Part B and standalone Part D drug plans. The second evaluation will focus on Medicare enrollee utilization patterns by setting—Stelara obtained in a physician's office (i.e., where injections would typically be administered by a health care provider) and Stelara obtained through a pharmacy (i.e., where injections would typically be self-administered at home).

Announced or Revised Agency Title Component Report Number(s) Expected Issue Date (FY)
Revised Centers for Medicare & Medicaid Services Medicare Payments for Stelara Office of Evaluation and Inspections OEI-BL-19-00500;
OEI-BL-19-00501
2024